Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have atrial fibrillation (an irregular heartbeat) that comes and goes on its own within 7 days, has not responded to medication, and whose doctor considers them a suitable candidate for an ablation procedure
- People aged 18 years or older
- People who are able and willing to attend all required check-up visits for the full length of the study
- People who are willing and able to give their formal written agreement to take part in this study
Who may not be able to join:
- People who have previously had a catheter ablation procedure for atrial fibrillation (such as pulmonary vein isolation or similar procedures)
- People who are already taking part in another clinical trial for an investigational drug or device, or any other trial that controls how their treatment is managed
- People whose atrial fibrillation is persistent (does not stop on its own) or long-standing persistent (has continued for a long time)
- People for whom their doctor considers an ablation procedure to be medically unsuitable for any known reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Brian Sanchez, MD, J & J Corporation
Phone: 615-448-5770
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module; Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 12-months.; Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 24-months.; Effectiveness of the QDOT Micro System use in conjunction with VISITAG SURPOINT Module at 36-months.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.